Apalutamide (Amorphous & Form B) API
Therapeutic Category
Anti-Cancer/ Oncology
Why Partner with Pinnacle Life Science
Regulatory Compliance
Manufactured under WHO-GMP compliant processes at our US FDA approved facility in Baddi, Himachal Pradesh.
Consistent Quality
Rigorous quality control at every stage ensures reliable purity and potency across every batch produced.
Global Reach
Trusted by pharmaceutical partners and distributors across 90+ countries worldwide.
Mechanism of Action
Abiraterone acetate, marketed under the brand name ZYTIGA, is an orally active inhibitor of the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is crucial in androgen biosynthesis and is expressed in testicular, adrenal, and prostatic tumour tissues. By inhibiting CYP17, abiraterone acetate reduces the production of testosterone and other androgens, which are key drivers of prostate cancer growth. The inhibition is both selective and irreversible, as it covalently binds to the enzyme, blocking androgen production at multiple sources: the testes, adrenal glands, and the tumor itself.
Contact Us
